MGIT系统漏检真实利福平耐药:英爱18个月监测的表型/基因型流行率
研究前瞻性收集英国和爱尔兰送检的二线药敏试验菌株,比较MGIT 960与蛋基培养基对利福平耐药的检测差异,并回顾分析2010至2014年存档菌株。结果显示MGIT漏检了部分rpoB突变株,但这类菌株在英爱流行率低,常规分子检测可发现假敏感。
要点
- MGIT系统可漏检部分rpoB突变导致的利福平耐药,表型与基因型结果不一致。
- 英爱地区此类漏检菌株流行率低,但常规分子检测有助于识别假敏感。
- 需进一步研究这些菌株与临床失败的关系及其他地区的流行率。
核心结论
- MGIT系统会漏检利福平耐药,英国和爱尔兰此类菌株流行率低,常规分子检测可发现假敏感。
研究设计与样本
- 前瞻性收集英国和爱尔兰所有送检二线药敏试验的菌株,并回顾分析2010至2014年存档的关键突变菌株。
主要发现
- 7234株前瞻性分离株中17株被纳入,所有菌株MGIT均敏感,17/17存在rpoB基因突变,D516Y最常见(13/17)。
- 回顾性发现10株关键基因型菌株,其中6/10 MGIT敏感而RR耐药;27株研究菌株中MGIT仅检出4株耐药。
关键数值与推荐
- 17株中1株RR临界(利福平MIC 4 mg/L)且PM耐药,8株RR耐药,8株RR高度耐药。
- 16株微量稀释法MIC在1至8 mg/L之间,PM法16/17敏感。
临床怎么用
- 对MGIT敏感但临床怀疑耐药者,应考虑分子检测以排除漏检。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize rifampicin-resistant strains missed by the Mycobacteria Growth Indicator Tube (MGIT) 960 system but not by egg-based media in the UK and Ireland and to ascertain their prevalence. METHODS: All strains sent for second-line susceptibility testing were prospectively collected. Drug Susceptibility Testing was performed by Resistance Ratio (RR), Proportion Method (PM), MGIT 960 and MIC determination by microdilution. Rifampicin-resistance-conferring mutations were detected with line probe assays and sequencing. At the end of the study period, retrospective archived strains from 2010 to 2014 showing key mutations were analysed phenotypically and genotypically. RESULTS: Seventeen of 7234 prospective isolates were included. All of them were susceptible by MGIT. One was borderline by RR (MIC to rifampicin of 4 mg/L) and was resistant by PM. Eight were resistant and eight were highly resistant on RR. These 16 isolates had MICs between 1 and 8 mg/L on microdilution. With PM, 16/17 were susceptible to rifampicin. 17/17 had mutations in the rpoB gene. D516Y was the mutation most frequently found (13/17). Retrospectively, ten additional strains with key genotypes were found in our collection: 6/10 were susceptible in the MGIT and resistant in RR. Of the 27 studied strains, the MGIT only detected resistance in four. CONCLUSIONS: Rifampicin resistance is missed by the MGIT system. In the UK and Ireland the prevalence of these strains is low. The introduction of routine molecular testing would detect false susceptibility. Further research is needed to ascertain the role of these strains in clinical failure and their prevalence in other settings.
引用
- Gonzalo X, Claxton P, Brown T, et al. True rifampicin resistance missed by the MGIT: prevalence of this pheno/genotype in the UK and Ireland after 18 month surveillance. Clin Microbiol Infect. 2016. PMID: 27903459. doi:10.1016/j.cmi.2016.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。